It's unsure whether using a cardiovascular Genetic Risk Score (cGRS) to target statin initiation in the primary prevention of atherosclerotic cardiovascular disease enhances clinical decision making or health outcomes Atherosclerotic Cardiovascular disease (ASCVD). Our goal was to calculate the cost-effectiveness of cGRS testing in guiding therapeutic decisions about statin commencement in people with a low-to-intermediate (2.5%-7.5%) 10-years ASCVD risk. For low- to intermediate-risk patients, testing for a 27-single-nucleotide polymorphism cardiovascular genetic risk score is often not a cost-effective technique for focusing statin medication in the primary prevention of atherosclerotic cardiovascular disease. The cost-effectiveness of cardiovascular genetic risk score testing is influenced by assumptions regarding statin disutility and cost, as well as age, gender, 10-years atherosclerotic cardiovascular disease risk, and willingness-to-pay threshold.
